Business
VYJUVEK (Krystal Biotech) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
Key market opportunities include the expansion of gene therapy approvals in dermatology, growing demand for durable rare disease treatments, increased investments in topical gene delivery technologies, and advancements in redosable therapy platforms, all amid rising chronic disease prevalence.Dublin, March 13, 2026 (GLOBE NEWSWIRE) -- The "VYJUVEK Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. The Vyjuvek mar
About this update from Krystal Biotech, Inc.
[{"type":"image","alt":"Company Logo","displaySize":"","headline":null,"caption":"Company Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":36,"url":"https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/g_3H8YP5.WdAX5cBtX03VA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65","width":300,"height":36}},"lazy":false},{"type":"text","content":"Key market opportunities include the expansion of gene therapy approvals in dermatology, growing demand for durable rare disease treatments, increased investments in topical gene delivery technologies, and advancements in redosable therapy platforms, all amid rising chronic disease prevalence.","length":294,"tagName":"p"},{"type":"text","content":"Dublin, March 13, 2026 (GLOBE NEWSWIRE) -- The "VYJUVEK Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering.","length":209,"tagName":"p"},{"type":"text","content":"The Vyjuvek market is experiencing significant growth driven by advancements in gene delivery technologies, emerging topical therapies, and increasing prevalence of chronic conditions. These developments, alongside regulatory support and innovations in redosable therapy platforms, are shaping the future of gene therapies in dermatology, particularly in treating rare genetic disorders.","length":387,"tagName":"p"},{"type":"text","content":"The ongoing research and breakthroughs in gene delivery vectors have expanded the scope of dermatological gene therapies, with topical solutions showing early success in clinical trials. The focus on rare genetic skin disorders is elevating the demand for innovative solutions, and Vyjuvek, with its functional COL7A1 gene delivery, addresses the critical needs of patients with dystrophic epidermolysis bullosa (DEB).","length":418,"tagName":"p"},{"type":"text","content":""Vyjuvek" is pivotal in progressing therapeutic approaches for DEB, promoting wound healing and enhancing skin strength through its topical gel formulated with the aim of achieving sustained collagen production. As chronic diseases become more prevalent, exacerbated by factors such as an aging population and envir...